We are improving the lives of people suffering from mental illness and substance use disorders

What we do

US Pharma

US Pharma

HQ & Pipeline

HQ & Pipeline

Digital Therapeutics

Digital Therapeutics

 Discover our story 

Key News

JANUARY 26, 2023
Orexo Interim Report Q4 2022, incl. Full Year Report

Go to PR

JANUARY 25, 2023
New blog post - "Charlie’s overdose: why we need to tell young people about fake pills"

Read the blog

JANUARY 18, 2023
Invitation to presentation of Orexo's Interim Report Q4 2022 incl. Full Year Report

Go to PR

Listed on Nasdaq Stockholm´s mainlist

Orexo is listed on Nasdaq Stockholm´s mainlist, Small Cap, (ORX), and can be traded in the US at the OTCQX Market (ORXOY).

Investor relations

MODIA® - our digital therapy for opioid use disorder

  • to be used along with pharmaceuticals
  • 180 days treatment
  • grounded in cognitive behavioral therapy techniques
  • available 24/7
  • ongoing clinical trial incl. more than 430 patients
Explore more

News Flow

Regulatory Press Releases

Press Releases & News

Orexo Social

31 January 2023

Klas Palin, hälsovårdsanalytiker på Erik Penser Bank, i en lång intervju med VD Nikolaj Sørensen. På agendan: Opera… https://t.co/8nhwCYB7hL

26 January 2023

O4 Report - Important steps forward in a challenging environment. Read the PR here: https://t.co/waSrsib4HC To just… https://t.co/coLzf86ELS

25 January 2023

Our Q4 Report will be published tomorrow at 8 am CET. In the afternoon at 2 pm investors, analysts & media are much… https://t.co/S1J4xbAa4o

Financial Snapshot

Group net revenues

624.3  MSEK

LTM1

Group EBITDA

-115.2 MSEK

LTM1

US Pharma segment EBIT

308.4 MSEK

LTM1

Cash position

359.1 MSEK

Q4 2022

1 Last Twelve Months, Q122-Q422, for more information about financial development Link